Pharmaceutical

Risk adjusted net present value: What is the current valuation of PMV Pharmaceuticals’s Rezatapopt?

Rezatapopt is a small molecule commercialized by PMV Pharmaceuticals, with a leading Phase II program in Endometrial Cancer.

Jul 2, 2024 - 04:00
Rezatapopt is a small molecule commercialized by PMV Pharmaceuticals, with a leading Phase II program in Endometrial Cancer.
Read the original article

Tags:

Previous Article

Risk adjusted net present value: What is the current valuation of Pfizer’s Atirm...

Next Article

Risk adjusted net present value: What is the current valuation of Pfizer’s Osive...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Report: Measles cases and deaths increase worldwide, as childhood vaccinations rates decline

Report: Measles cases and deaths increase worldwide, as...

Nov 17, 2023

Researchers try to tease out possible ties between long Covid and menopause

Researchers try to tease out possible ties between long...

Oct 20, 2023

Signal: Serum Institute of India plans to increase global reach

Signal: Serum Institute of India plans to increase glob...

Oct 7, 2023